GLIS family zinc finger 3Genealiases: NDH · ZNF515
Q-omics provides the consensus-scored GLIS3 profile across patient tissues and cancer cell-line models. GLIS3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GLIS3 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, GLIS3 RNA expression shows 19,062 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where GLIS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLIS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLIS3 survival associations across molecular data types. GLIS3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLIS3 RNA expression–survival associations across cancer types. High GLIS3 expression shows unfavorable associations in UVM, MESO, LUSC, LGG and BLCA, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GLIS3 RNA expression.
This table summarizes GLIS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GLIS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLIS3 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in HNSC, BRCA and STAD. The THCA box plot shows higher GLIS3 RNA expression in normal versus tumor tissue (log2 FC = −1.515, t-test p < 0.001).
This table shows molecular features associated with GLIS3 in patient tissues and cancer cell lines. In patient samples, GLIS3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GLIS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
